ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Aprea Receives Fast Track Designation, Orphan Drug Designation for APR-246
April 17, 2019Aprea Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to APR-246 for the treatment of patients with MDS having a TP53 mutation. -
Aprea Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246
August 03, 2017Aprea Therapeutics announced the first patient was enrolled in a Phase Ib/II clinical study of APR-246 in platinum-resistant high-grade serous ovarian cancer (HGSOC).
Pharma Sources Insight January 2025
